Surgery Partners (NASDAQ:SGRY - Get Free Report) is anticipated to release its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect the company to announce earnings of $0.1106 per share and revenue of $820.96 million for the quarter. Individuals may review the information on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.
Surgery Partners (NASDAQ:SGRY - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.04. The firm had revenue of $848.90 million for the quarter, compared to analyst estimates of $830.03 million. Surgery Partners had a negative net margin of 2.63% and a positive return on equity of 0.88%. Surgery Partners's quarterly revenue was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.17 earnings per share. On average, analysts expect Surgery Partners to post $0.25 EPS for the current fiscal year and $0.26 EPS for the next fiscal year.
Surgery Partners Stock Performance
SGRY opened at $23.21 on Monday. Surgery Partners has a 1-year low of $11.41 and a 1-year high of $23.37. The business has a 50 day moving average price of $15.13 and a two-hundred day moving average price of $14.64. The company has a market capitalization of $3.04 billion, a price-to-earnings ratio of -33.16 and a beta of 1.90. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.95 and a quick ratio of 1.78.
Insider Buying and Selling
In related news, Director Teresa DeLuca bought 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 18th. The shares were acquired at an average cost of $14.35 per share, with a total value of $143,500.00. Following the completion of the transaction, the director owned 66,843 shares of the company's stock, valued at approximately $959,197.05. The trade was a 17.59% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 2.00% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages have issued reports on SGRY. Weiss Ratings raised shares of Surgery Partners from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, October 16th. Benchmark reissued a "buy" rating on shares of Surgery Partners in a research report on Tuesday, August 11th. JPMorgan Chase & Co. raised their price target on Surgery Partners from $14.00 to $15.00 and gave the company a "neutral" rating in a report on Monday, September 14th. TD Cowen reaffirmed a "buy" rating and issued a $19.00 target price on shares of Surgery Partners in a report on Friday, September 18th. Finally, Cantor Fitzgerald cut Surgery Partners from an "overweight" rating to a "hold" rating in a research note on Monday, October 26th. Four investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $20.14.
View Our Latest Stock Analysis on Surgery Partners
Surgery Partners Company Profile
(
Get Free Report)
Surgery Partners, Inc is a U.S.-based healthcare services company that operates and manages ambulatory surgery centers and surgical hospitals. The company works with physicians, health systems and other healthcare providers to deliver outpatient surgical care in facilities designed for same-day procedures.
Its facilities provide surgical services across specialties such as orthopedics, pain management, ophthalmology, gastroenterology, urology, gynecology and general surgery. Surgery Partners also supports its operations with clinical, administrative and revenue-cycle services intended to help physicians and facility partners manage patient care and practice operations.
Founded in 2004 and headquartered in Brentwood, Tennessee, Surgery Partners has expanded its platform through acquisitions, joint ventures and other partnerships.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Surgery Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surgery Partners wasn't on the list.
While Surgery Partners currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.